-
Mashup Score: 1
Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML @ASH_hematology @StanfordDeptMed #ASH24 #Hematology https://t.co/Vc5OD1CtKC
-
-
Mashup Score: 0Understanding the Intricacies of CAR-T Cell Therapy and Care in Hematologic Malignancies - 13 day(s) ago
Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic malignancies.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
🔔 Dr. Sattva S. Neelapu, of @MDAndersonNews, discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic malignancies. #ASH24 #Hematology Read more from the interview here: https://t.co/OYQZpBHJFl
-
-
Mashup Score: 4100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis - 19 day(s) ago
Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
A 100-mg dose of bezuclastinib was safe and led to robust improvements in symptoms in patients with non-advanced systemic mastocytosis, according to findings from the phase 2 Summit trial. #ASH24 #hematology Read here: https://t.co/uppjIGOPZb
-
-
Mashup Score: 4100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis - 20 day(s) ago
Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
A 100-mg dose of bezuclastinib was safe and led to robust improvements in symptoms in patients with non-advanced systemic mastocytosis, according to findings from the phase 2 Summit trial. #ASH24 #hematology Read here: https://t.co/uppjIGOPZb
-
-
Mashup Score: 7
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis @IcahnMountSinai @MountSinaiNYC @ASH_hematology #ASH24 #hematology https://t.co/Yt29oVL3YY
-
-
Mashup Score: 2Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis - 1 month(s) ago
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis. @ash_hematology #ASH24 #hematology https://t.co/LEW55rJn84
-
-
Mashup Score: 7
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis @IcahnMountSinai @MountSinaiNYC @ASH_hematology #ASH24 #hematology https://t.co/Yt29oVL3YY
-
-
Mashup Score: 2Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis - 1 month(s) ago
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis. @ash_hematology #ASH24 #hematology https://t.co/LEW55rJn84
-
-
Mashup Score: 4A Final Chat with Our Clinician-Guides for ASH 2024 - 1 month(s) ago
Dr. Inas Abuali talks with Dr. Anjali Sharathkumar and Dr. Michael Williams about the major clinical takeaways from ASH 2024.
Source: cdn.jwplayer.comCategories: General Medicine News, General HCPsTweet-
Did you miss #ASH24? @inas_md chats with Dr. Anjali Sharathkumar and Dr. Michael Williams about the major clinical takeaways from the #hematology conference. https://t.co/Fl5NdYUrEc https://t.co/OgqIujFpbS
-
Ibrutinib/Venetoclax Combo Demonstrates Sustained TEAE-Free PFS in First-Line CLL @ASH_hematology @Rigshospitalet #ASH24 #Hematology https://t.co/wArg1Knu6F